MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a suspension order for a drug license of one of its stores in Telangana.

Regulatory Action Details

The suspension order was issued by the Assistant Director of Drugs Control Administration, Mahabubnagar, Telangana. The action affects a store situated at Jadcherla, Telangana, with the company receiving the order on April 08, 2026.

Financial Impact

The company has quantified the potential financial impact of this suspension. MedPlus Health Services estimates a potential revenue loss of Rs 0.28 lacs due to the two-day suspension of operations at the affected store.

Regulatory Compliance

The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in compliance with SEBI circulars dated July 13, 2023, and December 31, 2024. The violation falls under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Corporate Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on BSE and NSE websites. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on April 09, 2026.

Medplus health services Limited has completed its regulatory filing requirements by submitting the mandatory compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The pharmaceutical retail chain fulfilled its quarterly compliance obligations through proper documentation and filing procedures.

Regulatory Compliance Filing

The company filed the required certificate with stock exchanges on April 06, 2026, through Company Secretary and Compliance Officer Manoj Kumar Srivastava. The filing ensures adherence to SEBI (Depositories and Participants) Regulations, 2018, specifically under Regulation 74(5) requirements.

Stock Exchange Submissions

MedPlus Health Services submitted the compliance documentation to both major Indian stock exchanges where its shares are listed. The certificates were addressed to the listing departments of BSE Limited and National Stock Exchange of India Limited, ensuring comprehensive regulatory coverage.

Registrar Certification Process

KFIN Technologies Limited, serving as the company's Registrar and Transfer Agent, issued the compliance certificates on April 01, 2026. Deputy Vice President Bhaskar Roy signed the certificates confirming that securities dematerialization and rematerialization details were properly furnished to stock exchanges during the specified quarter.

Depository Compliance

The registrar submitted identical certificates to both major depositories in India - National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These submissions ensure complete compliance across the entire securities infrastructure ecosystem.

Document Availability

The compliance certificates are accessible through multiple channels for stakeholder reference. The company has made the documentation available on its official website at www.medplusindia.com , along with the websites of BSE Limited and National Stock Exchange of India Limited for transparent access to regulatory filings.